|
www.Xtremepicks.com: www.Xtremepicks.Com: Xtremepicks.Com Alerts For Tuesday, June 30, 2009: YGE, XCO, APPY, MEDX, And CNXT
(M2 PressWIRE Via Acquire Media NewsEdge) Xtremepicks.com Alerts for Tuesday include Yingli Green Energy Holding Company Limited (NYSE: YGE), EXCO Resources, Inc. (NYSE:XCO), AspenBio Pharma, Inc. (NASDAQ: APPY), Medarex, Inc. (NASDAQ:MEDX), and Conexant Systems, Inc. (NASDAQ: CNXT)
--- Yingli Green Energy Holding Company Limited (NYSE: YGE) opened Tuesday at $13.73 per share on trading volume of 2,140,000 shares.
In a press release out on June 30, 2009 -- Yingli Green Energy Holding Company Limited (NYSE: YGE) ("Yingli Green Energy"), one of the world's leading vertically integrated photovoltaic ("PV") product manufacturers, today announced that it closed the sale of an additional 2,790,000 American Depositary Shares ("ADSs"), each representing one ordinary share of Yingli Green Energy, at the public offering price of US$13.00 per share, pursuant to the over-allotment option exercised in full by the underwriters of its recent follow-on offering, which priced on June 16, 2008. The exercise of the over-allotment option brings the total number of ADSs sold by Yingli Green Energy in the follow-on offering to 18,390,000 and the aggregate net proceeds received by Yingli Green Energy to approximately US$227.4 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
About Yingli Green Energy
Yingli Green Energy Holding Company Limited (NYSE: YGE) is one of the world's leading vertically integrated PV product manufacturers. Yingli Green Energy designs, manufactures and sells PV modules and designs, assembles, sells and installs PV systems that are connected to an electricity transmission grid or operate on a stand-alone basis. Based in Baoding, China, Yingli Green Energy sells its PV modules to system integrators and distributors located in various markets around the world, including Germany, Spain, Italy, South Korea, Belgium, France, China and the United States.
--- EXCO Resources, Inc. (NYSE:XCO) opened Tuesday at $12.65 per share on trading volume of 7,590,000 shares.
In a press release out on Jun 30, 2009 -- EXCO Resources, Inc. (NYSE:XCO) ("EXCO") today announced that it has reached a definitive agreement with BG Group plc (LSE:BG.L) ("BG Group") for the joint development and operation of EXCO's Haynesville shale and certain other related natural gas assets located in East Texas/North Louisiana. In addition, EXCO and BG Group have reached an agreement in principle regarding the joint development and operation of EXCO's midstream assets in East Texas/North Louisiana.
About EXCO Resources, Inc.
EXCO Resources, Inc. is an oil and natural gas exploration, exploitation, development and production company headquartered in Dallas, Texas with principal operations in East Texas, North Louisiana, Appalachia, West Texas and the Mid-Continent.
--- AspenBio Pharma, Inc. (NASDAQ: APPY) opened Tuesday at $2.59 per share on trading volume of 154,882 shares.
In a press release out on Jun 30, 2009 -- AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-science company dedicated to the development of novel diagnostics and drugs for humans and animals, has filed a Premarket Notification [510(k)] with the U.S. Food and Drug Administration ("FDA") for its AppyScore(TM) Test, the first blood-based test designed as an aid in the diagnosis of human appendicitis.
About AspenBio Pharma, Inc.
AspenBio Pharma's mission is to be a leader in the development and commercialization of innovative products that address unmet diagnostic and therapeutic needs in both Human and Animal Health. Our Human Health Division is addressing the difficult challenge of diagnosing appendicitis in the hospital emergency department setting. Our Animal Health Division is focused on therapeutic proteins that support reproductive efficiency in animals of economic importance.
For more information, go to http://www.aspenbiopharma.com.
--- Medarex, Inc. (NASDAQ:MEDX) opened Tuesday at $8.37 per share on trading volume of 929,231 shares.
In a press release out on Jun 30, 2009 -- Medarex, Inc. (NASDAQ:MEDX) today announced it will receive a milestone payment of an undisclosed amount from Novartis Pharma AG (Novartis), in connection with the marketing approval from the U.S. Food and Drug Administration (FDA), to market Ilaris(R) (canakinumab, previously known as ACZ885) for the treatment of children as young as four years old and adults with cryopyrin-associated periodic syndrome, or CAPS, a serious life-long auto-inflammatory disease caused by rare genetic mutations.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology, product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently approved for commercial sale, the subject of regulatory applications for marketing authorization or in Phase 3 clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
--- Conexant Systems, Inc. (NASDAQ: CNXT) opened Tuesday at $1.27 per share on trading volume of 332,590 shares.
In a press release out on Jun 30, 2009 -- Conexant Systems, Inc. (NASDAQ: CNXT), a leading supplier of innovative semiconductor solutions for imaging, audio, video and Internet connectivity applications, today announced the first in a planned series of new system-on-chip (SoC) solutions targeted at the growing market for "connected" digital photo frames and interactive display appliances (IDAs). These products integrate Internet connectivity and touch-screen technology. The high-performance CX92735 supports advanced features including streaming media content, MP3 audio playback with slideshow functionality, and Wi-Fi(R), Bluetooth(R), and Ethernet connectivity.
About Conexant
Conexant's comprehensive portfolio of innovative semiconductor solutions includes products for imaging, video, audio, and Internet connectivity applications. Conexant is a fabless semiconductor company headquartered in Newport Beach, Calif. To learn more, please visit www.conexant.com.
Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.
Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ Back To LatinAmerica.tmcnet.com's Homepage 's Homepage ]
|
INDUSTRIES
Activate Email 
